Role of Vascular Inflammation in Coronary Artery Disease: Potential of Anti-inflammatory Drugs in the Prevention of Atherothrombosis

2014 ◽  
Vol 15 (1) ◽  
pp. 1-11 ◽  
Author(s):  
Daniel Medeiros Moreira ◽  
Roberto Leo da Silva ◽  
Jefferson Luís Vieira ◽  
Tammuz Fattah ◽  
Maria Emilia Lueneberg ◽  
...  
2018 ◽  
Vol 13 (1) ◽  
pp. 38 ◽  
Author(s):  
Alberto Lorenzatti ◽  
Maria Luz Servato ◽  
◽  
◽  

Coronary artery disease (CAD) is the leading cause of death worldwide. Despite notable advances in understanding the nature of atherosclerotic processes and the use of effective medications such as statins, there remains a significant residual risk. Even after optimal medical treatments and precise revascularisations, the recurrence of MI remains at approximately one-third for 5 years after an acute coronary syndrome (ACS). Over the past two decades, compelling data from animal and human studies has clearly identified atherosclerosis as an inflammatory disease of the arterial wall, but clinical applications related to this accumulated knowledge are still scarce. Recently, the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) has provided convincing evidence that an anti-inflammatory intervention with the monoclonal antibody canakinumab reduces cardiovascular events in well-treated CAD patients without affecting LDL cholesterol levels. This article presents a brief description of the role of inflammation in atherogenesis and examines selected anti-inflammatory interventions and their potential use in CAD-affected individuals.


Pharmacology ◽  
2018 ◽  
Vol 103 (3-4) ◽  
pp. 111-113 ◽  
Author(s):  
Gabriele Cortellini ◽  
Domenico Lippolis ◽  
Silvia Amati ◽  
Giancarlo Piovaccari ◽  
Fabio Cortellini ◽  
...  

To date, aspirin desensitization is employed with patients with nonsteroidal anti-inflammatory drugs (NSAIDs) exacerbated respiratory diseases (NERD) or with aspirin or NSAIDs hypersensitive patients needing a stent procedure for coronary artery disease. On the other hand, few data exist regarding aspirin desensitization in other cardiological features and particularly we haven’t data on different NSAIDs desensitization. Only for NERD patients we have data on ketorolac use. We report an efficacious desensitization procedure for ibuprofen in urticaria/angioedema patient with pericarditis and myocarditis associated.


2021 ◽  
pp. postgradmedj-2020-139611
Author(s):  
Arnav Katira ◽  
Ravish Katira

Coronary artery disease (CAD) is a major cause of morbidity and mortality worldwide. Inflammation has been seen to be a key feature of atherosclerosis and CAD, with a raised C-reactive protein being a marker of poor prognosis. Thus, the role of anti-inflammatory agents has been investigated in CAD. Colchicine is a well-known, inexpensive drug with marked anti-inflammatory effects. Here, we discuss the role of colchicine in stable CAD and post-acute coronary syndrome. We suggest that colchicine may play a key role in prevention of cardiovascular events in patients with stable and unstable CAD as colchicine is associated with a reduction in the rate of myocardial infarction and other major cardiovascular outcomes.


Author(s):  
Natascha Gaster ◽  
Lars Pedersen ◽  
Vera Ehrenstein ◽  
Morten Böttcher ◽  
Hans Erik Bøtker ◽  
...  

Abstract Aim To examine whether non-aspirin non-steroidal anti-inflammatory drugs (NSAID) use is associated with increased cardiovascular risks in patients with non-obstructive coronary artery disease (CAD). Methods and results Using Danish medical registries, we conducted a population-based cohort study in Western Denmark during 2008–2017. We identified all patients undergoing first-time coronary computed tomography angiography (CCTA) due to suspected CAD (n = 35,399), with results showing no (n = 28,581) or non-obstructive CAD (n = 6,818). Multivariate Cox regression was used to compute hazard ratios of major adverse cardiac events (MACE) including incident myocardial infarction, coronary intervention, or death. The rate of MACE increased by 33% for any NSAID use compared with non-use (hazard ratio 1.33, 95% confidence interval (CI) 1.06 to 1.68) in patients with no CAD and by 48% (1.48, 95% CI 1.06 to 2.07) in patients with non-obstructive CAD. Rate difference of MACE, per 100 person-years, was 0.38 (95% CI 0.08 to 0.67) in patients with no CAD (number needed to harm 267) and 1.08 (95% CI 0.06 to 2.11) in patients with non-obstructive CAD (number needed to harm 92). Current use of older COX-2 inhibitors was associated with the highest hazard ratio in patients with non-obstructive CAD, both when ascertained as pre-CCTA use (2.9-fold increase) and from time-varying use (1.8-fold increase). Conclusion NSAID use in patients with CCTA-confirmed no and non-obstructive CAD was associated with an increased cardiovascular risk compared with non-use. The absolute risk differences and numbers needed to harm were considered clinically relevant, particularly in patients with non-obstructive CAD.


2020 ◽  
Vol 25 (2) ◽  
pp. 113-118
Author(s):  
V. I. Shalnev

Inflammatory mediators play an important role in the pathogenesis of acute coronary syndrome (ACS). The results of experimental and randomized clinical trials on the role of various inflammation inhibitors in the treatment of coronary artery disease (CAD), in particular CANTOS and COLCOT, mark a new stage that can significantly change the clinical course and outcomes of the disease. We analyze our own experience in studying this problem. There are much prospects for the use of immunomodulatory and anti-inflammatory drugs reducing the residual inflammatory risk, but additional studies are needed to determine their role in the treatment of CAD.


2018 ◽  
Vol 254 ◽  
pp. 51 ◽  
Author(s):  
Kumar Ashish ◽  
Dhrubajyoti Bandyopadhyay ◽  
Samhati Mondal ◽  
Raktim Kumar Ghosh

Sign in / Sign up

Export Citation Format

Share Document